Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1219168-45-2

Post Buying Request

1219168-45-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1219168-45-2 Usage

General Description

Fmoc-6-chloro-DL-tryptophan is a chemical compound and an amino acid derivative that contains an Fmoc (9-fluorenylmethyloxycarbonyl) protective group attached to the amino group of the tryptophan molecule. The addition of a 6-chloro group to the tryptophan structure makes Fmoc-6-chloro-DL-tryptophan useful in peptide chemistry and solid phase peptide synthesis, as the chloro group can serve as a handle for further modifications. Fmoc-6-chloro-DL-tryptophan is often used in the synthesis of peptides and can be incorporated into peptide chains to introduce specific structural or functional properties. Its unique structure and reactivity make Fmoc-6-chloro-DL-tryptophan a valuable tool in chemical and biochemical research.

Check Digit Verification of cas no

The CAS Registry Mumber 1219168-45-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,9,1,6 and 8 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1219168-45:
(9*1)+(8*2)+(7*1)+(6*9)+(5*1)+(4*6)+(3*8)+(2*4)+(1*5)=152
152 % 10 = 2
So 1219168-45-2 is a valid CAS Registry Number.

1219168-45-2Downstream Products

1219168-45-2Relevant articles and documents

Structure-Based Design of Melanocortin 4 Receptor Ligands Based on the SHU-9119-hMC4R Cocrystal Structure ?

Martin, Charlotte,Gimenez, Luis E.,Williams, Savannah Y.,Jing, Yu,Wu, Yiran,Hollanders, Charlie,Van Der Poorten, Olivier,Gonzalez, Simon,Van Holsbeeck, Kevin,Previti, Santo,Lamouroux, Arthur,Zhao, Suwen,Tourwé, Dirk,Stevens, Raymond C.,Cone, Roger D.,Ballet, Steven

, p. 357 - 369 (2021)

The melanocortin receptors (MC1R-MC5R) belong to class A G-protein-coupled receptors (GPCRs) and are known to have receptor-specific roles in normal and diseased states. Selectivity for MC4R is of particular interest due to its involvement in various metabolic disorders, including obesity, feeding regulation, and sexual dysfunctions. To further improve the potency and selectivity of MC4R (ant)agonist peptide ligands, we designed and synthesized a series of cyclic peptides based on the recent crystal structure of MC4R in complex with the well-characterized antagonist SHU-9119 (Ac-Nle4-c[Asp5-His6-DNal(2′)7-Arg8-Trp9-Lys10]-NH2). These analogues were pharmacologically characterized in vitro, giving key insights into exploiting binding site subpockets to deliver more selective ligands. More specifically, the side chains of the Nle4, DNal(2′)7, and Trp9 residues in SHU-9119, as well as the amide linkage between the Asp5 and Lys10 side chains, were found to represent structural features engaging a hMC4R/hMC3R selectivity switch.

Tuning the Biological Activity of RGD Peptides with Halotryptophans ?

Kemker, Isabell,Schr?der, David C.,Feiner, Rebecca C.,Müller, Kristian M.,Marion, Antoine,Sewald, Norbert

, p. 586 - 601 (2021)

An array of l- and d-halotryptophans with different substituents at the indole moiety was synthesized employing either enzymatic halogenation by halogenases or incorporation of haloindoles using tryptophan synthase. Introduction of these Trp derivatives into RGD peptides as a benchmark system was performed to investigate their influence on bioactivity. Halotryptophan-containing RGD peptides display increased affinity toward integrin αvβ3 and enhanced selectivity over integrin α5β1. In addition, bromotryptophan was exploited as a platform for late-stage diversification by Suzuki-Miyaura cross-coupling (SMC), resulting in new-to-nature biaryl motifs. These peptides show enhanced affinity toward αvβ3, good affinity to αvβ8, and remarkable selectivity over α5β1 and αIIbβ3 while featuring fluorogenic properties. Their feasibility as a probe was demonstrated in vitro. Extensive molecular dynamics simulations were undertaken to elucidate NMR and high-performance liquid chromatography (HPLC) data for these late-stage diversified cyclic RGD peptides and to further characterize their conformational preferences.

PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF

-

Paragraph 0448; 0455, (2020/02/17)

The present disclosure describes the synthesis of peptidomimetic macrocycles and methods of using peptidomimetic macrocycles to treat a condition. The present disclosure also describes methods of using peptidomimetic macrocycles in combination with at least one additional pharmaceutically-active agent for the treatment of a condition, for example, cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1219168-45-2